Sign Out
Changes in liver function tests have been observed in some patients receiving Co-amoxiclav. The clinical significance of this change is uncertain but Co-amoxiclav should be used with caution in patients with evidence of hepatic dysfunction. Cholestatic jaundice, which may be severe but is usually reversible, has been reported rarely. Signs and symptoms may not become apparent up to six weeks after treatment ceased.
Erythematous rashes have been associated with granular fever in patients receiving amoxicillin. Co-amoxiclav should be avoided if granular fever is suspected. Prolonged use may also occasionally result in overgrowth of non-susceptible organisms.
Clavoxel-BID: Therefore dosage should be used with caution in patients with severe renal impairment.
